• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Upward Pressure on Drug Expenditures | 2023 Annual Managed Healthcare Executive Pharmacy Survey

Publication
Article
MHE PublicationMHE April 2023
Volume 33
Issue 4

COVID-19 is viewed as the condition putting the most upward pressure on drug expenditures, but over the next five years, respondents are eyeing migraine and hematologic cancers.

Although the COVID-19 pandemic seems to be receding and the public health emergency is scheduled to end on May 11, the respiratory disease ranked first as the condition that will account for putting the most upward pressure on drug expenditures in the 2023 Annual Managed Healthcare Executive Pharmacy Survey.

The 311 people who responded to the annual online survey Feb. 14-28 were allowed three picks among 11 conditions. Just over half (54%) had COVID-19 among their picks for conditions putting the greatest pressure on drug expenditures in 2023, followed by autoimmune disease (47%), diabetes (33%), hematologic (blood) cancers (31%) and hemophilia (30%).

When the time frame was extended to five years, COVID-19 was still top at the top of the table at 55%, but hematologic (blood) cancers (33%) and migraine (24%) nosed their way into being among the top picks.

Half (50%) of the respondents said benefit design to create incentives for patients to choose low-cost options was the most effective way to rein in pharmaceutical expenditures.

The respondents to the survey were spread fairly evenly across the various sectors of the U.S. healthcare industry, with 20% self-identifying as working for hospitals, 22% for physician practices, 19% for pharmacy benefit managers, 16% for payer organizations, 13% for drug and device manufacturers and the rest in a variety of sectors.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.